Fortis Capital Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$645K Buy
5,018
+1,350
+37% +$158K 0.07% 217
2026
Q1
$441K Buy
3,668
+1,763
+93% +$204K 0.06% 247
2025
Q4
$201K Buy
+1,905
New +$179K 0.03% 302
2025
Q3
Sell
-2,585
Closed -$205K 297
2025
Q2
$205K Sell
2,585
-105
-4% -$8.35K 0.04% 227
2025
Q1
$241K Buy
+2,690
New +$251K 0.05% 225
2023
Q2
Sell
-993
Closed -$106K 429
2023
Q1
$106K Buy
993
+15
+2% +$1.62K 0.06% 172
2022
Q4
$109K Buy
+978
New +$100K 0.06% 204

Other funds holding MRK

Fortis Capital Advisors's MRK Position: Q2 2026 in Review

Fortis Capital Advisors increased its Merck (MRK) stake by 37% in Q2 2026, buying an estimated $158K and bringing the position to 5,018 shares worth $645K. The position accounts for 0.07% of the portfolio, ranked #217.

Fortis Capital Advisors first reported a position in MRK in Q4 2022 and has held it in 7 quarters since. 2,083 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Fortis Capital Advisors held 5,018 shares of Merck worth $645K as of Q2 2026.
  • Fortis Capital Advisors bought 1,350 Merck shares in Q2 2026, an estimated $158K.
  • Merck made up 0.07% of Fortis Capital Advisors's portfolio in Q2 2026, its #217 holding.
  • Fortis Capital Advisors first reported a position in Merck in Q4 2022 and has held it in 7 quarters since.
  • 2,083 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Fortis Capital Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.